Navigation Links
The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development

MENLO PARK, Calif. and KANNAPOLIS, N.C., May 26 /PRNewswire/ -- The Immune Tolerance Institute, Inc. (ITI) and the David H. Murdock Research Institute (DHMRI) today announced a collaboration to establish the Center for Critical Path Research in Immunology (CCPRI) at The David H. Murdock Research Institute on the North Carolina Research Campus in Kannapolis, NC. Driven by a mission to accelerate the discovery and development of new breakthrough treatments for the millions of people afflicted with the broad range of immune system-related conditions, the CCPRI will integrate state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms to discover and develop novel biomarkers that more effectively guide new advances in human health and match patients with therapies that will provide them the greatest benefit. By joining forces to establish the CCPRI, ITI and DHMRI are creating a unique set of capabilities under one roof to accelerate the translation of basic discoveries into medical practice, and to become a major resource for a range of academic and industry partners. "The potential for this collaboration to reverse the effects of dreaded immune diseases now facing mankind is immeasurable," stated David H. Murdock, visionary and founder of the NC Research Campus.

"We are proud to be partners with the DHMRI in this enterprise," said Louis Matis, M.D. President and Chief Executive Officer of ITI. "There is growing consensus that applying more evidence-based understanding of disease to patient care will be critical to developing new therapies that are safer, targeted to the right patients, and thus more effective in disease prevention and treatment."

Biomarkers can enhance diagnostics and therapeutics development by helping to better predict the course of a disease, the likelihood of an individual's response to a medicine, as well as serving as surrogate endpoints of therapeutic efficacy and safety. Biomarkers were cited in the FDA's Critical Path Opportunities Report as one of the most critical areas for improving medical product development, shortening development times, reducing both costs and failure rates in drug development, and guiding better informed patient selection for targeted therapies.

"Advancing 'critical path' science will lead to new approaches to investigate the biological mechanisms of disease and to better predict the clinical efficacy and safety of emerging therapeutics. Such efforts have the potential to enhance human health and disease management and reverse the recent trends that have led to higher costs of medicine and slowed the pace of new treatment development," said Mike Luther, Ph.D., MBA, President of DHMRI. "In partnership with the ITI we will be able to identify new personalized medical solutions and make them widely available for patient benefit."

About ITI

The Immune Tolerance Institute (ITI) is a 501 (c)(3) non-profit corporation founded in partnership with the University of California, San Francisco (UCSF) to fill critical unmet needs for translating fundamental scientific discoveries into new therapies for the broad range of diseases related to the human immune system, including autoimmune diseases, allergy, asthma, cancer, and cardiovascular and infectious diseases. ITI is a milestone and value-driven, not-for-profit institute uniquely positioned at the intersection of academia and biopharma that is advancing a new paradigm for mechanism-based clinical development, designed to better correlate clinical outcomes with underlying disease mechanisms. The Institute's technologies are being deployed to perform comprehensive cellular, molecular and immunological assays on specimens obtained from patients during clinical trials of emerging immune therapeutics in order to identify novel biomarkers that can shorten drug development times, and reduce the costs of development and the number of drug failures in late-stage development. (

About the DHMRI

The David H. Murdock Research Institute was established as a nonprofit organization to support groundbreaking research at the North Carolina Research Campus (NCRC). Established through a private grant by David H. Murdock, the DHMRI, with its state of the art facilities and capabilities, was established to be the catalyst in the development of NCRC as a world class research campus. DHMRI and NCRC will host the world's leading scientists to promote a level of unprecedented scientific collaboration and public-private partnerships never before possible at the intersection of human, nutrition, and agriculture. (

SOURCE Immune Tolerance Institute
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoImmune Inc. Announces Shareholder Approval of Plan of Complete Liquidation and Dissolution
2. New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher
3. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
4. How immune cells sniff out bacteria
5. Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
6. Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction
7. Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
8. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
9. RNL BIO Rescues a College Student from Autoimmune Hearing Loss
10. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
11. Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
Post Your Comments:
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):